|Other Names||Glial fibrillary acidic protein, GFAP, GFAP|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2017d was selected from the S8 region of human GFAP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||GFAP, a class-III intermediate filament, is a cell- specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.|
|Cellular Location||Cytoplasm. Note=Associated with intermediate filaments|
|Tissue Location||Expressed in cells lacking fibronectin.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
GFAP is one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in the gene for GFAP cause Alexander disease, a rare disorder of astrocytes in the central nervous system.
Quintanar, J.L., et al., Parasitol. Res. 90(4):261-263 (2003).Shiroma, N., et al., Brain Dev. 25(2):116-121 (2003).Nielsen, A.L., et al., J. Biol. Chem. 277(33):29983-29991 (2002).Namekawa, M., et al., Ann. Neurol. 52(6):779-785 (2002).Lopez-Egido, J., et al., Exp. Cell Res. 278(2):175-183 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.